What they often do not walk out with is clarity about what lab work should accompany that prescription
Its 2025 guidance largely bars compounding of semaglutide and tirzepatide but recognizes limited circumstances where compounding may be appropriate, for example, when a prescriber documents a specific change that results in a significant difference for an identified patient
Kreymann B, Williams G, Ghatei MA, Bloom SR
Overall meal composition matters
Further, these product candidates may compete with our product candidates in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing
When administered together, their mechanisms converge to amplify appetite regulation, energy intake reduction, and glycemic improvements, exceeding the individual effects of monotherapy by acting on complementary neuroendocrine circuits regulating body weight and metabolism 1-3